In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
10.1210/en.2013-1096 65
Pigmentation Reduction: Lightens skin by reducing melanin production, evening out skin tone
Jiang Q, Jiang G, Shi KQ, Cai H, Wang YX, Zheng MH
Research is also growing about the potential benefits of combining GLP-1s with the menopausal hormone treatment (MHT) that has long been recommended, and there are new companies to support the regimen
In addition, the present work employs the precision medicine approach [51] to define a Long COVID model which links the acute inflammation of COVID-19 with IO&NS pathways and the neuropsychiatric symptoms 34 months later